Head-To-Head Survey: BioLargo (BLGO) vs. Its Rivals

BioLargo (NASDAQ:BLGOGet Free Report) is one of 32 public companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its rivals? We will compare BioLargo to similar businesses based on the strength of its earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares BioLargo and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioLargo $12.23 million -$3.50 million -8.00
BioLargo Competitors $6.84 billion $211.64 million 68.77

BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 70.6% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.6% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for BioLargo and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
BioLargo Competitors 139 1251 1567 44 2.51

As a group, “Chemicals & allied products” companies have a potential upside of 14.63%. Given BioLargo’s rivals higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its rivals.

Risk & Volatility

BioLargo has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.81, suggesting that their average stock price is 81% more volatile than the S&P 500.

Profitability

This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
BioLargo Competitors -591.84% 5.15% -0.65%

Summary

BioLargo rivals beat BioLargo on 8 of the 10 factors compared.

About BioLargo

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.